Martine A. Rothblatt, who serves as both Chairperson and Chief Executive Officer of United Therapeutics Corp. (NASDAQ:UTHR), has executed a significant stock transaction involving the sale of common shares. On June 12, 2026, Rothblatt sold 9,500 shares of the company's common stock, generating proceeds of approximately $5.14 million. The shares were sold at prices ranging between $537.3999 and $545.7116 per unit. This transaction is part of a broader set of activities involving the company's equity, reflecting the ongoing management of executive holdings within the biotechnology sector.
Concurrently with the sale, Rothblatt acquired 9,500 shares of common stock through the exercise of stock options. These options were exercised at a price of $146.03 per share, resulting in an approximate value of $1.39 million. Both the acquisition through option exercise and the subsequent sale were facilitated under a pre-arranged 10b5-1 trading plan. This specific plan was adopted on November 7, 2025, and is scheduled to remain in effect until the earlier of two conditions: the exercise of 1,734,410 stock options expiring on March 15, 2027, or December 31, 2026. The use of such plans is a standard mechanism for executives to manage equity compensation while adhering to regulatory guidelines regarding insider trading.
Following these recent transactions, Rothblatt's direct ownership in United Therapeutics stands at 40,513 shares. Her indirect ownership is more complex, involving multiple family trusts and her spouse. Specifically, she holds indirect ownership of 166 shares through her spouse, 324,443 shares in family trusts where she shares investment power and is a beneficiary, 249,108 shares in family trusts where her spouse is the sole trustee or co-trustee, 45,596 shares in family trusts where her spouse shares investment power, and 8,902 shares in family trusts where she is the sole trustee or co-trustee. This extensive indirect ownership structure highlights the significant equity stake retained by the company's leadership.
The stock transaction comes shortly after United Therapeutics reported its first-quarter financial results, which failed to meet analyst expectations. The company reported revenue of $781.5 million, falling short of the anticipated $797.4 million. A key product, Tyvaso, contributed $457.5 million to this total, also missing the expected $478.6 million. Net income for the quarter was recorded at $274.9 million, compared to the consensus estimate of $320.5 million. Despite these misses, there were positive developments in the company's clinical pipeline. The TETON-1 phase 3 study of Tyvaso for idiopathic pulmonary fibrosis successfully met its primary endpoint, as published in the New England Journal of Medicine. The study highlighted Tyvaso's ability to preserve lung function and reduce clinical worsening events.
Additionally, United Therapeutics announced a collaboration with Varda Space Industries to explore microgravity-based pharmaceutical processing. This partnership aims to enhance the stability and bioavailability of treatments for rare pulmonary diseases, indicating a strategic move into novel manufacturing techniques within the pharmaceutical industry. Analyst reactions to the company's performance have been mixed. TD Cowen reiterated its Buy rating on the stock, maintaining a price target of $675.00. Conversely, BTIG reiterated a Neutral rating following the first-quarter earnings miss.
At the time of reporting, United Therapeutics' stock was trading at $549.57, reflecting a market capitalization of $23.3 billion. The stock has delivered a remarkable 90% return over the past year. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value. The company's financial performance and executive trading activities continue to be closely watched by investors in the biotechnology and healthcare sectors, as they assess the balance between clinical progress and financial execution.